J&J pledges not to enforce TB patents in certain countries

In a move welcomed by healthcare charities, Johnson & Johnson (J&J) has confirmed that it will not enforce patents it owns and controls for Sirturo (bedaquiline) in the treatment of multidrug-resistant tuberculosis (MDR-TB) in 134 low-and middle-income countries.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

Explainer: ARIPO’s role in Plant Variety Protection

15 July 2025 Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.

Africa

Commercialising genomic tech in Nigeria

29 April 2025 Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.

Africa

South Africa: Hope for measures to prevent abuse of the patent system

9 May 2023 Government-led schemes to incentivise patents are leading to delays and prejudice against legitimate applicants. Tyron Grant of Spoor and Fisher explains how South Africa is tackling the problem.

More features

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

J&J pledges not to enforce TB patents in certain countries

More on this story

Editor's picks

Editor's picks

More features